Pharma Backs UK Parliament Report As 'No Deal Brexit' Fears Grow
The pharmaceutical sector has given its backing to a report from MPs which warns that a no-deal Brexit will have a hugely damaging effect on the industry in the country, turning it into "a second-tier state for new and innovative medicines."
You may also be interested in...
The managing director for Sanofi in the UK says clinical trials there will become less likely in future if access to innovative drugs doesn't improve, causing comparative standards of care to deteriorate.
A report from the UK House of Commons business committee on its inquiry into the impact of Brexit on the pharma sector has flagged up the multiple challenges facing companies and regulators.
Pharmaceutical companies have been urged by the European Commission to press ahead with their contingency planning for Brexit, amid signs some firms are taking a “wait-and-see” approach.